Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcoma

Patients with metastatic angiosarcoma undergoing chemotherapy, radiation, and/or surgery experience a median progression free survival of less than 6 months and a median overall survival of less than 12 months. Given the aggressive nature of this cancer, angiosarcoma clinical responses to chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Amaya, Clarissa N., Perkins, Mariah, Belmont, Andres, Herrera, Connie, Nasrazadani, Arezo, Vargas, Alejandro, Khayou, Thuraieh, Montoya, Alexa, Ballou, Yessenia, Galvan, Dana, Rivas, Alexandria, Rains, Steven, Patel, Luv, Ortega, Vanessa, Lopez, Christopher, Chow, William, Dickerson, Erin B., Bryan, Brad A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978448/
https://www.ncbi.nlm.nih.gov/pubmed/29854879
http://dx.doi.org/10.18632/oncoscience.413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978448/
https://www.ncbi.nlm.nih.gov/pubmed/29854879
http://dx.doi.org/10.18632/oncoscience.413

Ejemplares similares